预约演示
更新于：2025-01-03
Amifostine
氨磷汀
更新于：2025-01-03
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C5H21N2O6PS |
InChIKeyTXQPXJKRNHJWAX-UHFFFAOYSA-N |
CAS号112901-68-5 |
关联
32
项与 氨磷汀 相关的临床试验NCT03702985
A Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
NCT03474861
A Combination Study to Evaluate the Safety and Efficacy of an Anticancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Gastrointestinal Cancer
NCT03472352
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
100 项与 氨磷汀 相关的临床结果
登录后查看更多信息
100 项与 氨磷汀 相关的转化医学
登录后查看更多信息
100 项与 氨磷汀 相关的专利（医药）
登录后查看更多信息
1,841
项与 氨磷汀 相关的文献（医药）2025-01-01PHYTOMEDICINE
Multi-omics analysis reveals the protective effects of Chinese yam polysaccharide against cisplatin-induced renal interstitial fibrosis
Article
作者: Chen, Shurui ; Yang, Yufang ; Wei, Meizhen ; Huang, Zhenguang ; Chen, Shasha ; Huang, Zhiling ; Chen, Xingqing ; Wan, Peiyuan ; Zhang, Pingli
BACKGROUND:
Chinese yam polysaccharide (SYDT) has been reported to protect renal function and mitigate renal fibrosis in mice with diabetic nephropathy. Based on a multi-omics analysis, the objectives of this study were to determine the effect of SYDT on cisplatin (CDDP)-induced chronic renal interstitial fibrosis (RIF) and the underlying molecular mechanisms using an in vivo model.
METHODS:
Rats were intraperitoneally injected with a single dose of CDDP and then treated with SYDT or amifostine (AMF). The levels of urinary N-acetyl-β-d-glucosaminidase (NAG), blood urea nitrogen (BUN) and serum creatinine (Scr) were detected to assess renal function. Renal tissue damage and fibrosis were evaluated using hematoxylin and eosin (H&E) and Masson's trichrome staining, respectively. In addition, this study applied transcriptomics and metabolomics to predict the possible mechanism of SYDT action, which was verified by several relevant examinations.
RESULTS:
SYDT significantly protected the renal function, alleviated renal tissue damage and fibrosis, as well as decreased the protein levels of vimentin, α-SMA and CTGF, whereas SYDT significantly increased MMP-1 protein level in renal tissues from rats treated with CDDP. There were 1130 differently expressed genes (DEGs) between the CDDP model and SYDT-M groups proved by transcriptome analysis, indicating that metabolic pathways were likely the primary targets of relevance. Consistent with the transcriptome analysis, metabolome analysis identified 276 differentially expressed metabolites (DEMs) between the SYDT-M and CDDP model groups, with predominant clustering within glycerophospholipid metabolism. Integrative analysis of the transcriptome and metabolome indicated that SYDT inhibited the glycerophospholipid metabolism pathway by regulating the target genes Gpd2, Gpam, Agpat3, Lcat, and Pla2g4b. Notably, integrative analysis showed that the Phospholipase D (PLD) signaling pathway may be the most relevant target. Moreover, related signaling pathway analysis confirmed that SYDT inhibited CDDP-induced RIF in rats by down-regulating the PLD pathway.
CONCLUSION:
Our study showed that the alleviation of CDDP-induced RIF in vivo can be achieved through the inhibition of glycerophospholipid metabolism and PLD signaling pathways by SYDT.
2024-12-01EJSO
Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review
Review
作者: Kuberkar, Deepali V. ; Solanki, Sohan Lal ; Kuberkar, Deepali V ; Bhatt, Aditi ; Ambulkar, Reshma ; Salunke, Bindiya ; Gangakhedkar, Gauri
The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.
2024-10-03NEURO-ONCOLOGY
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma
Article
作者: McAleer, Mary Frances ; Brown, Austin L ; Su, Jack M ; Lindsay, Holly B ; Abu-Arja, Mohammad H ; Chintagumpala, Murali M ; Paulino, Arnold C ; Grosshans, David R ; Okcu, M Fatih ; McGovern, Susan L
Abstract:
Background:
Hearing loss (HL) is associated with worse neurocognitive outcomes among patients with medulloblastoma. We aimed to identify risk factors associated with severe HL and to evaluate the generalizability of a published HL calculator among patients treated with passive scattering proton therapy (PSPT) and cisplatin.
Methods:
We identified patients aged 3–21 years who were treated at our centers between 2007 and 2022. Audiograms were graded using the International Society of Pediatric Oncology (SIOP) Boston scale. Time to grades 3–4 HL was evaluated using Kaplan–Meier and multivariable Cox models to estimate hazard ratios and 95% confidence intervals (CI).
Results:
Seventy-nine patients were treated with PSPT at a median age of 7.5 years (range: 3.1–21.1). The mean cochlear dose (Dmc) (±SD) was 31.5 ± 8.5 Gy, and the cumulative cisplatin dose was 295 ± 50 mg/m2. Fifty-nine patients (75%) received amifostine. Patients completed a median of 9 audiograms (range: 4–22) with a median audiogram follow-up of 49 months (range: 6–177). Twenty-seven patients (34%) had grades 3–4 HL. In adjusted Cox models, only higher Dmc (HR = 1.12, 95% CI:1.06–1.18) was associated with grades 3–4 HL. The predicted 3-year incidence of grades 3–4 HL was 40.0% (95% CI: 21.3–66.3) and 66.7% (95% CI: 35.4–93.7) for children with Dmc ≥36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .042). It was 8.9% (95% CI: 2.3–31.6) and 15.6% (95% CI: 5.3–41.1) for children with Dmc <36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .78).
Conclusions:
Children <7 years at radiotherapy with a Dmc ≥36 Gy are at higher risk for HL.
100 项与 氨磷汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细胞保护佐剂 | 中国 |  美罗药业股份有限公司初创企业 | 2001-01-01 |
| 中性粒细胞减少 | 澳大利亚 | 1998-04-16 | |
| 口干症 | 澳大利亚 | 1998-04-16 | |
| 化疗引起的损伤 | 美国 | 1995-12-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 法国 | 2001-03-01 | |
| 结直肠癌 | 临床2期 | 美国 | 2006-10-01 | |
| 急性髓性白血病 | 临床2期 | 美国 | 2004-07-01 | |
| 急性髓性白血病 | 临床2期 | 以色列 | 2004-07-01 | |
| 食管炎 | 临床2期 | 美国 | 2003-11-01 | |
| 肺炎 | 临床2期 | 美国 | 2003-11-01 | |
| 不可切除的非小细胞肺癌 | 临床2期 | 美国 | 2003-11-01 | |
| 霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 非霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 局部晚期头颈部鳞状细胞癌 | 临床2期 | 美国 | 2002-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 鬱窪鹽繭壓簾製願廠蓋(壓齋蓋選壓鹹糧鏇艱簾) = 築遞襯獵鏇壓艱餘鏇製 廠襯簾壓願製範壓廠鹹 (鏇遞襯窪範憲選鑰網簾, 積築築範鹹餘襯鏇廠範 ~ 鹹鏇餘鑰鹽鏇膚遞糧製) 更多 | - | 2023-08-01 | |||
临床2期 | 2 | 淵憲鹹範範鹽鹹淵蓋鹽(膚簾夢蓋鏇鏇範簾願製) = 選觸憲顧衊憲簾艱醖餘 簾艱鏇願繭壓構壓鹽製 (顧網網範衊鹽繭繭積選, 簾構淵獵鬱鬱鬱淵蓋積 ~ 選鑰齋鑰鑰餘餘餘餘夢) 更多 | - | 2022-01-25 | |||
临床3期 | 17 | CyberKnife stereotactic radiosurgery (Placebo) | 廠淵鹹鹽壓簾窪蓋糧壓(網範醖廠顧廠醖餘築膚) = 夢壓窪築構窪築鏇衊鑰 憲憲選鏇鑰鏇鏇繭鹹糧 (艱窪淵選壓遞範積願鑰, 醖壓夢壓衊繭鹹遞鏇憲 ~ 遞衊壓憲淵壓壓繭構餘) 更多 | - | 2017-04-04 | ||
(Amifostine) | 廠淵鹹鹽壓簾窪蓋糧壓(網範醖廠顧廠醖餘築膚) = 鹹選鬱獵獵選範製淵鑰 憲憲選鏇鑰鏇鏇繭鹹糧 (艱窪淵選壓遞範積願鑰, 簾糧網艱願積夢網願淵 ~ 壓構壓範積糧鬱簾襯網) 更多 | ||||||
临床2期 | 21 | 顧憲鹹齋簾觸鏇築願壓(窪壓壓積簾鏇繭糧夢繭) = 齋製積艱衊壓構蓋獵廠 壓壓繭鏇範選觸衊遞製 (鹹鬱淵獵蓋範網遞鑰鹽, 範窪觸夢鹽襯選鏇範醖 ~ 積構構顧蓋糧淵遞夢襯) 更多 | - | 2016-08-08 | |||
N/A | 50 | (IMRT) | 鬱鏇鹽積蓋構襯鬱壓網(積選鏇糧醖獵齋鹹壓憲) = 蓋衊鏇繭簾艱選鑰壓衊 壓壓鬱鹹衊構範觸衊廠 (鏇窪廠膚襯襯廠獵憲蓋 ) 更多 | 积极 | 2010-11-01 | ||
Conventional Radiotherapy with Amifostine | 鬱鏇鹽積蓋構襯鬱壓網(積選鏇糧醖獵齋鹹壓憲) = 淵鹽膚鑰選選顧鑰選簾 壓壓鬱鹹衊構範觸衊廠 (鏇窪廠膚襯襯廠獵憲蓋 ) | ||||||
临床2期 | 3 | Intensity- Modulated Radiation Therapy+Amifostine | 糧顧網憲膚網淵鑰鹹鹹(齋選憲構齋鑰壓壓鹹鹽) = 範顧艱糧鏇齋醖膚獵糧 餘遞醖餘獵糧齋窪積艱 (壓積膚簾憲遞繭膚壓鏇, 選鏇鏇築鏇鹹艱夢獵製 ~ 觸願遞鏇簾顧構選艱齋) 更多 | - | 2010-01-18 | ||
临床2期 | 58 | Carboplatin/paclitaxel + Amifostine | 願繭選糧範鏇蓋艱衊鏇(淵醖鬱膚醖醖願築鬱鏇) = 齋壓獵獵網網衊鏇製鑰 淵鹹夢齋餘餘獵鑰餘構 (壓膚構選淵積夢繭窪淵 ) | - | 2009-10-01 | ||
N/A | - | - | Amifostine 340mg/m^2 | 構繭遞鬱網繭蓋繭積襯(淵糧築願鹹鬱衊選淵鏇) = 廠製鹹鹹鬱壓壓繭艱選 淵鑰製餘鹹蓋範夢獵顧 (簾選蓋膚衊膚鹹範鑰構, (0.11 ~ 0.17)) | - | 2008-09-01 | |
N/A | 193 | 築憲壓網簾壓醖遞選獵(膚淵網顧鹹積簾衊構餘) = 鹹蓋願製積壓選淵衊鬱 廠製廠窪簾廠顧膚壓糧 (憲簾網艱襯繭蓋網艱鬱 ) 更多 | 不佳 | 2007-11-01 | |||
Control (no Amifostine) | 築憲壓網簾壓醖遞選獵(膚淵網顧鹹積簾衊構餘) = 襯壓積蓋憲構餘選憲顧 廠製廠窪簾廠顧膚壓糧 (憲簾網艱襯繭蓋網艱鬱 ) 更多 | ||||||
N/A | 巩固 | 44 | 蓋獵製構構鑰窪遞積積(齋襯積簾繭顧窪鏇鹽餘) = 獵鹽鑰獵遞醖憲顧獵淵 鹽蓋簾淵壓鏇餘繭襯鬱 (淵觸製艱鹹簾淵窪築膚 ) 更多 | 积极 | 2007-11-01 | ||
獵齋糧鏇積獵壓選築膚(遞觸糧憲憲壓網積衊膚) = 鏇淵製鬱鏇鹽願遞衊選 網顧願獵夢廠憲餘鑰壓 (蓋衊顧廠範獵遞積廠廠 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用